Sorafenib for recurrent hepatocellular carcinoma after liver transplantation

Dok Hyun Yoon, Baek Yeol Ryoo, Min Hee Ryu, Sung Gyu Lee, Shin Hwang, Dong Jin Suh, Han Chu Lee, Tae Won Kim, Chul Soo Ahn, Ki Hun Kim, Deok Bog Moon, Yoon Koo Kang

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Objective: Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials. The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined. Methods: We retrospectively analyzed 13 patients who were treated with sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Results: The median time to recurrence from liver transplantation was 12.3 months(95% confidence interval: 8.5-16.1 months). Six of 10 evaluable patients showed stable disease, which was the best response and the median duration of stabilization was 3.9 months (95% confidence interval: 1.6-6.2 months). At a median follow-up duration of 3.7 months (range: 0.3-10.9 months) in surviving patients, the median time to progression and the median overall survival from commencement of sorafenib were 2.9 months (95% confidence interval: 0.0-6.8 months) and 5.4 months (95% confidence interval: 3.7-7.0 months), respectively. Grade 3 neutropenia was observed in one patient, which was the only high-grade hematologic toxicity observed. Grade 3 hand-foot skin reactions were observed in three patients. Adverse events could be managed with dose adjustment. Conclusions: These findings suggest that sorafenib may be a feasible treatment option regarding its efficacy and safety for recurrent hepatocellular carcinoma after liver transplantation.

Original languageEnglish (US)
Article numberhyq055
Pages (from-to)768-773
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number8
DOIs
StatePublished - May 21 2010
Externally publishedYes

Keywords

  • Hepatocellular carcinoma
  • Immunosuppressant
  • Liver transplantation
  • Sorafenib

Fingerprint

Dive into the research topics of 'Sorafenib for recurrent hepatocellular carcinoma after liver transplantation'. Together they form a unique fingerprint.

Cite this